131 related articles for article (PubMed ID: 7622306)
1. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.
Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H
Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306
[TBL] [Abstract][Full Text] [Related]
2. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
3. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
4. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression.
Guinee DG; Travis WD; Trivers GE; De Benedetti VM; Cawley H; Welsh JA; Bennett WP; Jett J; Colby TV; Tazelaar H
Carcinogenesis; 1995 May; 16(5):993-1002. PubMed ID: 7767998
[TBL] [Abstract][Full Text] [Related]
5. Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients.
Cressey R; Pimpa S; Chewaskulyong B; Lertprasertsuke N; Saeteng S; Tayapiwatana C; Kasinrerk W
BMC Biotechnol; 2008 Feb; 8():16. PubMed ID: 18284706
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer.
Oshikawa K; Sugiyama Y
Respir Med; 2000 Nov; 94(11):1085-91. PubMed ID: 11127496
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
8. Serum p53 antibodies as early markers of lung cancer.
Lubin R; Zalcman G; Bouchet L; Trédanel J; Legros Y; Cazals D; Hirsch A; Soussi T
Nat Med; 1995 Jul; 1(7):701-2. PubMed ID: 7585154
[TBL] [Abstract][Full Text] [Related]
9. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.
Mitsudomi T; Suzuki S; Yatabe Y; Nishio M; Kuwabara M; Gotoh K; Hatooka S; Shinoda M; Suyama M; Ogawa M; Takahashi T; Ariyoshi Y; Takahashi T
J Natl Cancer Inst; 1998 Oct; 90(20):1563-8. PubMed ID: 9790550
[TBL] [Abstract][Full Text] [Related]
11. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer.
Top B; Mooi WJ; Klaver SG; Boerrigter L; Wisman P; Elbers HR; Visser S; Rodenhuis S
Int J Cancer; 1995 Apr; 64(2):83-91. PubMed ID: 7615358
[TBL] [Abstract][Full Text] [Related]
13. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.
Angelopoulou K; Yu H; Bharaj B; Giai M; Diamandis EP
Clin Biochem; 2000 Feb; 33(1):53-62. PubMed ID: 10693987
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
16. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.
Ryder SD; Rizzi PM; Volkmann M; Metivier E; Pereira LM; Galle PR; Naoumov NV; Zentgraf H; Williams R
J Clin Pathol; 1996 Apr; 49(4):295-9. PubMed ID: 8655704
[TBL] [Abstract][Full Text] [Related]
17. Molecular and immunological aspects of p53 and p53-autoantibodies in head and neck squamous cell carcinoma.
Cordes C; Von Lingen J; Görögh T; Ambrosch P; Gottschlich S; Hoffmann M
Oncol Rep; 2009 Dec; 22(6):1299-303. PubMed ID: 19885580
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
Regidor PA; Regidor M; Callies R; Schindler AE
Eur J Gynaecol Oncol; 1996; 17(3):192-9. PubMed ID: 8780917
[TBL] [Abstract][Full Text] [Related]
19. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer.
Hammel P; Leroy-Viard K; Chaumette MT; Villaudy J; Falzone MC; Rouillard D; Hamelin R; Boissier B; Remvikos Y
Int J Cancer; 1999 May; 81(5):712-8. PubMed ID: 10328221
[TBL] [Abstract][Full Text] [Related]
20. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O
Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
